Genfit : Une publication sans surprise
>Une trésorerie de 62 M€ à fin juin - Les résultats semestriels de Genfit sont solides avec une trésorerie de 61,6 M€ à fin juin. Celle-ci sera d’autant plus accentuée par le versement, lors de ce T3, de 48,7 M€ correspondant à la première vente d’Iqirvo d’Ipsen aux Etats-Unis. De plus, Genfit devrait recevoir 26,5 M€ dans ces prochains mois venant de l’approbation réglementaire et du lancement du médicament en Europe. Du fait de cette trésorerie, le groupe a une...Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.